Testing for high-risk human papillomaviruses every five years – even with a self-collected sample – is the “preferred screening strategy” for cervical cancer starting at age 30, according to a new ...

John Donne Potter received funding from the Health Research Council of New Zealand for this work. Naomi Brewer does not work for, consult, own shares in or receive funding from any company or ...

Roche’s CINtec PLUS Cytology is the only FDA-approved and CE-marked dual-stain test to triage human papillomavirus (HPV)-positive cervical cancer screening test results Dual-stain biomarkers aid in ...